On March 23, 2020 IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"), a leader in pharmaceutical films, reported that it will release its fourth quarter and full-year 2019 financial results before market open on Thursday, March 26, 2020 (Press release, IntelGenx, MAR 23, 2020, View Source [SID1234555746]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As previously announced, the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 26, 2020 for completion of its review of IntelGenx’s 505(b)(2) New Drug Application ("NDA") for RIZAPORT VersaFilm for the treatment of acute migraines.

In order to facilitate a discussion on both the financial results and the FDA’s anticipated decision on the RIZAPORT NDA, a conference call has been scheduled for Friday, March 27. The call will be hosted by Dr. Horst G. Zerbe, Chief Executive Officer, and Mr. Andre Godin, President and Chief Financial Officer. Details of the conference call and webcast are below:

Date: Friday, March 27, 2020

Time: 8:30 a.m. ET

Conference dial-in: (833) 231-8269

International dial-in: (647) 689-4114

Conference ID: 5685777

Live Webcast Registration: Click here